VRTX Q3 2022 Earnings — Vertex Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

VRTXVertex Pharmaceuticals Incorporated

$129B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2.3B+17.6% YoY

Gross Profit

$2.0B87.6% margin

Operating Income

$1.1B48.3% margin

Net Income

$931M39.9% margin

EPS (Diluted)

$3.59

QoQ Revenue Growth

+6.3%

Cash Flow

Operating Cash Flow

$956M

Free Cash Flow

$901M

Stock-Based Comp.

$136M

Balance Sheet

Total Assets

$16.7B

Total Liabilities

$3.7B

Stockholders' Equity

$13.0B

Cash & Equivalents

$9.2B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.3B	$2.0B	+17.6%
Gross Profit	$2.0B	$1.7B	+17.0%
Operating Income	$1.1B	$1.1B	+6.8%
Net Income	$931M	$852M	+9.2%

Revenue Segments

TRIKAFTA/KAFTRIO

$2.0B86%

ORKAMBI

$146M6%

KALYDECO

$139M6%

SYMDEKO/SYMKEVI

$38M2%

Geographic Segments

UNITED STATES

$1.5B62%

Europe

$731M31%

Other, Non U.S.

$148M6%